Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation
作者:Haiyan Kong、Xianshe Meng、Rui Hou、Xiaoxiao Yang、Jihong Han、Zhouling Xie、Yajun Duan、Chenzhong Liao
DOI:10.1016/j.bmcl.2021.128051
日期:2021.7
developing human monoamine oxidase B (hMAO-B) inhibitors as anti-Parkinson’s disease (PD) drugs. However, low efficiency and unwanted side effects of the marketed hMAO-B inhibitors hamper their medical applications, therefore, novel potent selective hMAO-B inhibitors are still of great interest. Herein we report 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as hMAO-B inhibitors, which
在开发人类单胺氧化酶 B (hMAO-B) 抑制剂作为抗帕金森病 (PD) 药物方面取得了成功。然而,市售 hMAO-B 抑制剂的低效和有害副作用阻碍了它们的医疗应用,因此,新型有效的选择性 hMAO-B 抑制剂仍然很受关注。在此,我们报告了 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1 H -indene-4-thiol 衍生物作为 hMAO-B 抑制剂,它们是通过采用基于片段的药物设计策略设计的将雷沙吉兰与疏水片段连接起来。在合成的 31 种化合物中,K8和K24表现出非常令人鼓舞的 hMAO-B 抑制活性和对 hMAO-A 的选择性,优于雷沙吉兰和 safinamide。体外研究表明K8和K24对神经组织细胞无毒,它们对 ROS 形成和潜在的神经保护活性有相当大的作用。进一步的小鼠行为试验表明,这两种化合物对 MPTP 诱导的 PD 模型小鼠具有良好的治